AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Psychedelicalpha

Published November 13, 2026 · Updated November 14, 2026

Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA

Read the full story at Psychedelicalpha

Our Editor, Josh Hardman, shares his notes from a recent trip to D.C. as three psychedelic new drug applications sit before the FDA.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Ibogaine